drugset / Trial / NCT04221971
NK Cell Infusion for Patients With Acute Myeloid Leukemia
Phase 1
Unknown
10 enrolled
Peking University People's Hospital
The University of Science and Technology of China · collab
NaSingle-groupOpen-labelTreatment
Summary
Natural killer (NK) cells exert antitumor effects via their cytotoxic and cytokine-secreting capacity without present of clinical symptoms. In recent years, with the continuous advancement of in vitro expansion methods, the application of good quality management technology, NK cells could be clinical grade expanded without the need for pre-purification, feeder-free, and serum-free culture. In this clinical trial the investigators want to demonstrate the safety and efficacy chemotherapy combined with donor-derived in vitro activated NK cells infusion for high risk AML patients.
Timeline
- Start
- 2020-10
- Primary completion
- 2021-04
- Completion
- 2022-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | 1e+07 cells/kg | Other |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |